36 results on '"Laterza MM"'
Search Results
2. Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy
- Author
-
Angelica Petrillo, Maria Maddalena Laterza, Luca Pompella, Fortunato Ciardiello, Erika Martinelli, Vincenzo Famiglietti, Gennaro Galizia, Michele Orditura, Jole Ventriglia, Giuseppe Tirino, Ferdinando De Vita, Annalisa Pappalardo, Petrillo, A, Laterza, Mm, Tirino, G, Pompella, L, Ventriglia, J, Pappalardo, A, Famiglietti, V, Martinelli, E, Ciardiello, F, Orditura, M, Galizia, G, and De Vita, F.
- Subjects
0301 basic medicine ,Oncology ,Adult ,Blood Platelets ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Neutrophils ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Systemic inflammation ,Disease-Free Survival ,Metastatic gastric cancer ,03 medical and health sciences ,0302 clinical medicine ,Stomach Neoplasms ,Internal medicine ,medicine ,Biomarkers, Tumor ,Humans ,In patient ,Lymphocyte Count ,Aged ,Retrospective Studies ,Neutrophil-lymphocyte ratio ,Aged, 80 and over ,Inflammation ,Chemotherapy ,Performance status ,business.industry ,fungi ,Cancer ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,First line chemotherapy ,medicine.symptom ,business ,Platelet-lymphocyte ratio - Abstract
Aim: Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score to predict survival in metastatic GC (mGC) before first-line chemotherapy. Materials & methods: We studied the prognostic value of neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio in 151 patients with mGC at the diagnosis. Results: Median overall survival (OS) was significantly lower in patients with high NLR. Performance status 1–2 according to the Eastern Cooperative Oncology Group scale and NLR were predictors of shorter OS at multivariate analysis. Based on these results, we defined a prognostic OS score, showing a better median OS in favorable risk group. Conclusion: Elevated pretreatment NLR and Eastern Cooperative Oncology Group are independent predictors of shorter OS in mGC patients before first-line chemotherapy.
- Published
- 2018
3. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study
- Author
-
Francesco Iovino, Carlo Castoro, Landino Fei, A. Farella, F. De Vita, Eva Lieto, Vincenzo Napolitano, Alberto Ruol, N. Di Martino, Michele Orditura, Maria Maddalena Laterza, Gennaro Galizia, Giovanni Conzo, Roberto Pacelli, Sabrina Rossetti, Alessio Fabozzi, Ermanno Ancona, Fortunato Ciardiello, Valentina Gambardella, Floriana Morgillo, Orditura, M, Galizia, G, Di Martino, N, Ancona, E, Castoro, C, Pacelli, Roberto, Morgillo, F, Rossetti, S, Gambardella, V, Farella, Antonio, Laterza, Mm, Ruol, A, Fabozzi, A, Napolitano, V, Iovino, F, Lieto, E, Fei, L, Conzo, G, Ciardiello, F, and De Vita, F.
- Subjects
medicine.medical_specialty ,Preoperative chemoradiotherapy ,Multivariate analysis ,business.industry ,Locally advanced ,Cancer ,Original Articles ,medicine.disease ,Confidence interval ,Surgery ,Regimen ,medicine ,Adenocarcinoma ,business ,Chemoradiotherapy - Abstract
Background: To date, few studies of preoperative chemotherapy or chemoradiotherapy (crt) in gastroesophageal junction (gej) cancer have been statistically powered; indeed, gej tumours have thus far been grouped with esophageal or gastric cancer in phase iii trials, thereby generating conflicting results. Methods: We studied 41 patients affected by locally advanced Siewert type i and ii gej adenocarcinoma who were treated with a neoadjuvant crt regimen [folfox4 (leucovorin–5-fluorouracil–oxaliplatin) for 4 cycles, and concurrent computed tomography–based threedimensional conformal radiotherapy delivered using 5 daily fractions of 1.8 Gy per week for a total dose of 45 Gy], followed by surgery. Completeness of tumour resection (performed approximately 6 weeks after completion of crt), clinical and pathologic response rates, and safety and outcome of the treatment were the main endpoints of the study. Results: All 41 patients completed preoperative treatment. Combined therapy was well tolerated, with no treatment-related deaths. Dose reduction was necessary in 8 patients (19.5%). After crt, 78% of the patients showed a partial clinical response, 17% were stable, and 5% experienced disease progression. Pathology examination of surgical specimens demonstrated a 10% complete response rate. The median and mean survival times were 26 and 36 months respectively (95% confidence interval: 14 to 37 months and 30 to 41 months respectively). On multivariate analysis, TNM staging and clinical response were demonstrated to be the only independent variables related to long-term survival. Conclusions: In our experience, preoperative chemoradiotherapy with folfox4 is feasible in locally advanced gej adenocarcinoma, but shows mild efficacy, as suggested by the low rate of pathologic complete response.
- Published
- 2014
4. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
- Author
-
Teresa Troiani, Guido Giordano, Angelica Petrillo, B. Savastano, Maria Maddalena Laterza, A. Diana, Alessio Fabozzi, Giovanni Conzo, Fortunato Ciardiello, Antonio Febbraro, Ferdinando De Vita, Gennaro Galizia, Jole Ventriglia, Michele Orditura, DE VITA, Ferdinando, Ventriglia, J, Febbraro, A, Laterza, Mm, Fabozzi, A, Savastano, B, Petrillo, A, Diana, A, Giordano, G, Troiani, Teresa, Conzo, Giovanni, Galizia, Gennaro, Ciardiello, Fortunato, and Orditura, Michele
- Subjects
Compassionate Use Trials ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_treatment ,Deoxycytidine ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,Neoplasm Metastasis ,Randomized Controlled Trials as Topic ,Combination chemotherapy ,Middle Aged ,Treatment Outcome ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Female ,medicine.symptom ,Carcinoma, Pancreatic Ductal ,Research Article ,medicine.drug ,Adult ,medicine.medical_specialty ,Paclitaxel ,Nausea ,Neutropenia ,Nab-paclitaxel ,Drug Administration Schedule ,03 medical and health sciences ,Albumins ,Internal medicine ,medicine ,Metastatic pancreatic cancer ,Genetics ,Humans ,Aged ,Retrospective Studies ,Chemotherapy ,Performance status ,business.industry ,medicine.disease ,Survival Analysis ,Gemcitabine ,Pancreatic Neoplasms ,Clinical trial ,030104 developmental biology ,business - Abstract
BACKGROUND: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. METHODS: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m(2) Nab-P and 1 g/m(2) gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67 (range 41-77) years, and 11 patients were aged ≥70 years. RESULTS: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %) patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy. Median carbohydrate antigen 19-9 level was 469 U/l (range 17.4-61546 U/l) and 29 patients (70.7 %) had referred pain at the time of diagnosis. Patients received a median six cycles (range 1-14) of treatment. Overall response rate was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966-8.034), and median overall survival was 10 months (95 % CI 7.864-12.136). Treatment was well tolerated. No grade 4 toxicity was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %), anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %). Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 % according to the Karnofsky scale. CONCLUSIONS: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall response rate, progression-free survival and overall survival, with a good safety profile. Background: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone. Methods: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m2 Nab-P and 1 g/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67 (range 41-77) years, and 11 patients were aged ≥70 years. Results: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %) patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy. Median carbohydrate antigen 19-9 level was 469 U/l (range 17.4-61546 U/l) and 29 patients (70.7 %) had referred pain at the time of diagnosis. Patients received a median six cycles (range 1-14) of treatment. Overall response rate was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966-8.034), and median overall survival was 10 months (95 % CI 7.864-12.136). Treatment was well tolerated. No grade 4 toxicity was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %), anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %). Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 % according to the Karnofsky scale. Conclusions: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall response rate, progression-free survival and overall survival, with a good safety profile.
- Full Text
- View/download PDF
5. Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab-paclitaxel therapy outcome in advanced gastric cancer: results of prospective study.
- Author
-
D'Alessandro R, Refolo MG, Schirizzi A, De Leonardis G, Donghia R, Guerra V, Giannelli G, Lolli IR, Laterza MM, De Vita F, Messa C, and Lotesoriere C
- Abstract
[This corrects the article DOI: 10.3389/fonc.2022.862116.]., (Copyright © 2023 D’Alessandro, Refolo, Schirizzi, De Leonardis, Donghia, Guerra, Giannelli, Lolli, Laterza, De Vita, Messa and Lotesoriere.)
- Published
- 2023
- Full Text
- View/download PDF
6. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
- Author
-
Arrichiello G, Perrone A, Napolitano S, Martini G, De Falco V, Incoronato P, Laterza MM, Facchini G, Famiglietti V, Nacca V, Paragliola F, Napolitano R, Suarato G, Nicastro A, Martinelli E, Ciardiello D, Ciardiello F, and Troiani T
- Subjects
- Humans, Male, Adult, Middle Aged, Aged, Aged, 80 and over, Female, Trifluridine pharmacology, Trifluridine therapeutic use, Bevacizumab pharmacology, Bevacizumab therapeutic use, Retrospective Studies, Uracil therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms pathology, Colonic Neoplasms drug therapy
- Abstract
Background: The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited., Objective: The aim of our work was to provide further evidence on the activity and safety of this combination in a real-world series of Western mCRC patients refractory or intolerant to previous therapies., Patient and Methods: We conducted a retrospective, observational study of patients with mCRC refractory or intolerant to standard therapies. Patients were treated with trifluridine-tipiracil and bevacizumab. Previous therapy with fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab, aflibercept, regorafenib, and cetuximab or panitumumab (only RAS wild-type) was allowed, as was previous participation in clinical trials. Clinicopathological characteristics, overall response rate (ORR), disease control rate (DCR), overall survival (OS), PFS, and safety data were retrospectively collected and analyzed., Results: We recorded 31 patients treated between 1 December 2017 and 30 June 2022. Median age was 69 years (range 38-82 years), 39% were male, 100% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1, tumor location was left-sided in 77% of cases, 54% had synchronous presentation, 35% were RAS mutant, 3% were BRAF mutant, and 71% underwent primary tumor resection; 64% of patients had liver metastases, 55% had lung metastases, and 23% had peritoneal carcinomatosis. The median number of previous treatment lines was 2 (range 0-5), and 84% of patients received at least one previous anti-angiogenic agent. The ORR and DCR were 3% and 71%, respectively. With a median follow-up of 8 months (range 2-39), median PFS was 6 months (95% confidence interval [CI] 3.1-8.9 months) and median OS was 14 months (95% CI 10.1-17.8 months). Adverse events of any grade were reported in 58% of patients. The most common grade 3-4 toxicities were neutropenia (19%) and anemia (6%); 35% of patients required either dose delays or dose reductions due to toxicity. Granulocyte colony-stimulating factor (G-CSF) prophylaxis was administered either on first or subsequent cycles of treatment in 35% of patients. No treatment-related deaths occurred. Sixty percent of the patients who discontinued treatment eventually received one or more lines of subsequent therapy., Conclusions: Our series provides further evidence on the activity and safety of the combination of trifluridine-tipiracil and bevacizumab in a real-world series of Western refractory mCRC patients., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
7. Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab-Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study.
- Author
-
D'Alessandro R, Refolo MG, Schirizzi A, De Leonardis G, Donghia R, Guerra V, Giannelli G, Lolli IR, Laterza MM, De Vita F, Messa C, and Lotesoriere C
- Abstract
The combination of paclitaxel and ramucirumab is the second-line therapy of choice in the treatment of advanced gastric cancer. To date, no biomarkers are available in gastric cancer to predict the outcome of antiangiogenic therapy. The present prospective study included 35 patients undergoing second-line therapy with ramucirumab and paclitaxel. Serum samples were systematically collected from the beginning of therapy and at each cycle until disease progression. Multiplex analysis of a panel of angiogenic factors identified markers for which the changes at defined time intervals were significantly different in patients with progression-free survival ≤3 (Rapid Progression Group) compared to those with progression-free survival >3 (Control Disease Group). Comparative analysis revealed significantly different results in the two groups of patients for VEGFC and Angiopoietin-2, both involved in angiogenesis and lymphangiogenesis. VEGFC increased in the progressive-disease group, while it decreased in the control-disease group. This decrease persisted beyond the third cycle, and it was statistically significant compared to the basal level in patients with longer progression-free survival. Angiopoietin-2 decreased significantly after 2 months of therapy. At progression time, there was a significant increase in VEGFC and Angiopoietin-2, suggesting the activation pathways counteracting the blockade of VEGFR2 by ramucirumab. Overall results showed that a greater change in VEGFC and Angiopoietin-2 levels measured at the beginning of the third cycle of therapy corresponded to a lower risk of progression and thus to longer progression-free survival., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 D’Alessandro, Refolo, Schirizzi, De Leonardis, Donghia, Guerra, Giannelli, Lolli, Laterza, De Vita, Messa and Lotesoriere.)
- Published
- 2022
- Full Text
- View/download PDF
8. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
- Author
-
Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, and Facchini G
- Subjects
- Animals, Antineoplastic Agents, Immunological adverse effects, Carcinoma, Hepatocellular immunology, Carcinoma, Hepatocellular metabolism, Carcinoma, Hepatocellular pathology, Humans, Immune Checkpoint Inhibitors adverse effects, Liver Neoplasms immunology, Liver Neoplasms metabolism, Liver Neoplasms pathology, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Carcinoma, Hepatocellular therapy, Immune Checkpoint Inhibitors therapeutic use, Immune Tolerance, Immunotherapy adverse effects, Liver Neoplasms therapy, Tumor Escape, Tumor Microenvironment immunology
- Abstract
In contrast to several tumors whose prognoses are radically affected by novel immunotherapeutic approaches and/or targeted therapies, the outcomes of advanced hepatocellular carcinoma (HCC) remain poor. The underlying cirrhosis that is frequently associated with it complicates medical treatment and often determines survival. The landscape of HCC treatment had included sorafenib as the only drug available for ten years, until 2018, when lenvatinib was approved for treatment. The second-line systemic treatments available for hepatocellular carcinoma include regorafenib, cabozantinib, ramucirumab, and, more recently, immune checkpoint inhibitors. However, the median survival remains below 15 months. The results obtained in clinics should be interpreted whilst considering the peculiar role of the liver as an immune organ. A healthy liver microenvironment ordinarily experiences stimulation by gut-derived antigens. This setup elucidates the response to chronic inflammation and the altered balance between tolerance and immune response in HCC development. This paper provides an overview of the mechanisms involved in HCC pathogenesis, with a special focus on the immune implications, along with current and future clinical perspectives.
- Published
- 2021
- Full Text
- View/download PDF
9. Treatment options after regorafenib failure in metastatic colorectal cancer.
- Author
-
Berretta M, Fiorica F, Quagliariello V, Laterza MM, Facchini G, and Montopoli M
- Subjects
- Humans, Pyridines therapeutic use, Colonic Neoplasms, Phenylurea Compounds therapeutic use
- Published
- 2021
- Full Text
- View/download PDF
10. Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells.
- Author
-
Laterza MM, Ciaramella V, Facchini BA, Franzese E, Liguori C, De Falco S, Coppola P, Pompella L, Tirino G, Berretta M, Montella L, Facchini G, Ciardiello F, and de Vita F
- Abstract
The anti-HER2 monoclonal antibody trastuzumab is a key drug for the treatment of HER2-positive gastric cancer (GC); however, its activity is often limited by the onset of resistance and mechanisms of resistance are still poorly understood. Several targeted agents showed synergistic activity by concomitant use with trastuzumab in vitro and are under clinical investigation. The aim of this study was to assess the antitumor activity of duligotuzumab, an anti HER3/EGFR antibody or ipatasertib, an AKT inhibitor, combined with trastuzumab in a panel of HER2-positive human gastric cancer cells (GCC), and the efficacy of such combinations in HER2-resistant cells. We have assessed the efficacy of duligotuzumab or ipatasertib and trastuzumab in combination, analyzing proliferation, migration and apoptosis and downstream intracellular signaling in vitro on human HER2-positive GCC (NCI-N87, OE33, OE19) and in negative HER2 GCC (MKN28). We observed a reduction of proliferation, migration and apoptotic rate in HER2-positive OE33, OE19 and N87 cell lines with the combination of duligotuzumab or ipatasertib plus trastuzumab. In particular, in OE33 and OE19 cell lines, the same combined treatment inhibited the activation of proteins downstream of HER2, HER3, AKT and MAPK pathways. Targeting both HER2 and HER3, or HER2 and AKT, results in an improved antitumor effect on HER2-positive GCC.
- Published
- 2021
- Full Text
- View/download PDF
11. The use of 68 Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities.
- Author
-
Franzese E, Falco S, Laterza MM, Montella L, Facchini S, Liguori C, Coppola P, Diessa Y, Berretta M, Pisconti S, Trama F, Ferro M, Crocetto F, Fasano M, Buonerba C, and Facchini G
- Abstract
Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
- Published
- 2021
- Full Text
- View/download PDF
12. Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report.
- Author
-
Tirino G, Petrillo A, Pompella L, Pappalardo A, Laterza MM, Panarese I, Sabetta R, Franco R, Galizia G, Ciardiello F, and De Vita F
- Abstract
Background: The prognosis of patients with advanced gastric cancer remains overall poor despite some recent innovations and the development of new therapeutic approaches. Current European guidelines do not recommend any specific treatment for patients with advanced gastric cancer refractory to two or more previous chemotherapy regimens, making this setting "orphan." Immunotherapy is quickly evolving also for this malignancy even if with controversial results and the correct patient selection is still debated, especially for Western patients. The phase III ONO-4538-12 "ATTRACTION-2" represents the current landmark trial for the development of immunotherapy for pretreated Asian patients and led to the approval of Nivolumab in some Asian countries, while only previous phase trials are available for Caucasians. Complete radiological response is anecdotic and has never been described both in the pivotal trial both in the others with Western patients enrolled. Case presentation: We report two cases of heavily pretreated Western elderly patients with metastatic gastric cancer who experienced durable complete radiological response to Nivolumab "off label" (more than 20 months to date) in a clinical practice context. Molecular analysis of potential predictive factors has been performed (PD-L1, EBV, MSI, and TMB) on primary tumor sample. Conclusions: Despite the lack of evidence for Western patients and the controversial outcome with the use of checkpoint inhibitors in previous settings, immunotherapy may dramatically change the prognosis and the natural history of pretreated Western metastatic gastric cancer, in a correctly selected population. Microsatellite instability and tumor mutational burden may be reliable predictive factors also for Caucasians. There is an urgent need for a change in clinical practice also for this "orphan" patients and more efforts are needed in order to clarify the role of predictive factors for a correct patient selection and better chances of survival for this awful malignancy., (Copyright © 2020 Tirino, Petrillo, Pompella, Pappalardo, Laterza, Panarese, Sabetta, Franco, Galizia, Ciardiello and De Vita.)
- Published
- 2020
- Full Text
- View/download PDF
13. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population.
- Author
-
Petrillo A, Tirino G, Zito Marino F, Pompella L, Sabetta R, Panarese I, Pappalardo A, Caterino M, Ventriglia A, Laterza MM, Morgillo F, Orditura M, Ciardiello F, Franco R, and De Vita F
- Abstract
Purpose: ATTRACTION-2 trial assessed the role of Nivolumab as a new standard treatment for Asian patients with pretreated metastatic gastric cancer (mGC). The aim of this analysis was to evaluate the safety and efficacy of Nivolumab in a real-life Western population, considering the lack of evidence to date., Patients and Methods: Patients progressed after ≥2 chemotherapy regimens and able to receive Nivolumab (3 mg/kg q14) were eligible for the analysis., Results: 16 patients received Nivolumab as third (81.3%) or fourth line (18.7%) from September 2017 to July 2019. The safety was in line with the literature and only one patient discontinued treatment due to persistent hematological toxicity. Overall response rate and disease control rate were 18.7% and 31.2%, respectively. Median duration of response was 5 months. With a median follow-up of 21 months, median OS was 6 months (7, 21 and 22 months in the responders) and median PFS 3 months. PD-L1 and microsatellite status were retrospectively collected in 12 patients. All the major responders were MSI, although no statistically significant difference in OS or PFS was observed according to molecular analysis., Conclusion: Nivolumab is feasible and effective in Western patients with mGC. Further investigation is urgently needed also in non-Asians., Competing Interests: A.Pe: honoraria from Lilly; G.T: travel accommodation from Italfarma, Servier; M.O.: Honoraria from Italfarmaco, EISAI, epionpharma, Roche; F.C: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda; F.D.V: Advisory Boards: Roche, Amgen, Celgene, Lilly. The authors declare that all these conflicts of interest are not connected with the issue of this paper. The other authors have no conflicts of interest to declare. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results., (© 2020 Petrillo et al.)
- Published
- 2020
- Full Text
- View/download PDF
14. First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age.
- Author
-
Petrillo A, Pappalardo A, Calabrese F, Tirino G, Pompella L, Ventriglia J, Laterza MM, Caterino M, Sforza V, Iranzo V, Biglietto M, Orditura M, Ciardiello F, Conzo G, Molino C, and De Vita F
- Abstract
Background: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the elderly as first-line treatment for mPC., Methods: We retrospectively analyzed the data of 64 mPC patients (≥65 years old) treated according to the MPACT schedule., Results: Median age was 69.5 years (range, 65-80 years); after a median of 5 cycles administered (range, 1-12), the most common adverse events (AEs) were grade 2 alopecia (46.9%), anemia (17.2%) and hypertransaminasemia (10.9%); all grades neutropenia occurred in 20.3% of pts. Global incidence of grade 3 and 4 toxicities were 26.5% and 0%, respectively, and no patients stopped treatment due to unacceptable toxicity. Stable disease (SD) was observed in 31.2% of patients, with a disease control rate (DCR) and overall response rate of 57.8% and 26.6%, respectively. After a median follow-up of 18 months, median progression free survival (PFS) was 8 months (95% CI: 6.3-9.6) and median OS was 12.0 months (95% CI: 8.4-15.6). The univariate analysis for overall survival (OS) showed that only ECOG performance status was an independent prognostic factor for survival., Conclusions: Nab-paclitaxel plus gemcitabine schedule is feasible and effective in the "daily clinical practice" geriatric population., Competing Interests: Conflicts of Interest: A Petrillo: Honoraria from Lilly. V Sforza: honoraria from Celgene for “proyecto enlace” and during that period he collected these data. F Ciardiello: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda. M Orditura: Honoraria from Italfarmaco, EISAI, epionpharma, Roche. F De Vita: Advisory Boards: Roche, Amgen, Celgene, Lilly. The other authors have no conflicts of interest to declare., (2019 Journal of Gastrointestinal Oncology. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
15. Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
- Author
-
Petrillo A, Pappalardo A, Pompella L, Tirino G, Calabrese F, Laterza MM, Caterino M, Ventriglia A, Orditura M, Conzo G, Molino C, Ciardiello F, Biglietto M, and De Vita F
- Subjects
- Adenocarcinoma drug therapy, Adult, Aged, Chemotherapy, Adjuvant methods, Deoxycytidine therapeutic use, Disease-Free Survival, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Gemcitabine, Pancreatic Neoplasms, Albumins therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Deoxycytidine analogs & derivatives, Neoplasm Recurrence, Local drug therapy, Paclitaxel therapeutic use, Pancreatic Neoplasms drug therapy
- Abstract
Nab-paclitaxel plus gemcitabine (Nab-Gem) represents one of the standard regimen for first-line treatment of metastatic pancreatic adenocarcinoma (mPDAC). However, few data are available in mPDAC relapsed after gemcitabine as adjuvant treatment. Our study aims to evaluate the efficacy and feasibility of Nab-Gem as first-line treatment for mPDAC patients previously treated with adjuvant treatment. We retrospectively analyzed the safety and efficacy data of 36 patients, who received first-line Nab-Gem after gemcitabine as adjuvant treatment. All patients received gemcitabine after radical surgery. Median disease-free survival was 12 months (95% CI 9.7-14.3); at relapse, all patients received Nab-Gem. We observed an objective response rate and disease control rate of 11.1% and 63.9%, respectively. With a median follow-up of 47 months, median progression-free survival was 5 months (95% CI 1.0-9.0), whereas median overall survival (OS) was 13 months (95% CI 5.5-20.5). Median OS was higher in patients with a relapse ≥ 7 months after the end of adjuvant treatment than in patients relapsed < 7 months (14 vs. 8 months, respectively, p: 0.52). Our results show that first-line Nab-Gem is feasible and effective in patients previously treated with gemcitabine as adjuvant treatment.
- Published
- 2019
- Full Text
- View/download PDF
16. Increased circulating levels of vascular endothelial growth factor C can predict outcome in resectable gastric cancer patients.
- Author
-
Petrillo A, Laterza MM, Tirino G, Pompella L, Pappalardo A, Ventriglia J, Savastano B, Auricchio A, Orditura M, Ciardiello F, Galizia G, and De Vita F
- Abstract
Background: Neoangiogenesis has proven to be a relevant pathogenetic mechanism in gastric cancer (GC) and lymphatic spread represents an important well-known prognostic factor. Vascular endothelial growth factor C (VEGF-C) plays a key role in lymphangiogenesis and its blood levels in GC patients are easily measurable. This analysis aimed to investigate the prognostic role of preoperative VEGF-C blood levels., Methods: VEGF-C serum levels were determined by enzyme-linked immunoadsorbent assay (ELISA) in 186 patients observed at our institution from January 2004 until December 2009 and 82 healthy subjects. Statistical analyses were performed using SPSS 21.0., Results: VEGF-C levels were significantly higher in GC patients (median: 287.4 pg/mL; range, 76.2-865.2 pg/mL) than in the control group (median VEGF-C: 31 pg/mL; range, 12-97 pg/mL). A significant correlation between VEGF-C levels, T, N and tumor stage has been described. The median overall survival (OS) was statistically significantly higher in pts with low serum VEGF-C levels [median: not reached (NR) vs. 26 months; P<0.0001]. Higher preoperative VEGF-C levels correlated also with earlier disease relapse and poor disease-free survival (DFS) (median NR in each subgroup, P=0.005). Furthermore, high VEGF-C levels [hazard ratio (HR) =2.7; P=0.018] and tumor grading (HR =0.44; P=0.007) were independent prognostic factors for OS at multivariate analysis., Conclusions: Our study showed that increased VEGF-C levels are significantly associated with advanced regional lymph node involvement and poor OS and DFS in pts with resected GC paving the way to a possible application as prognostic factor in the clinical practice., Competing Interests: Conflicts of Interest: F Ciardiello: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda; F De Vita: Advisory Boards: Roche, Amgen, Celgene, Lilly; M Orditura: Honoraria from Italfarmaco, EISAI, epionpharma, Roche; A Petrillo: honoraria from Lilly. The authors declare that all these conflicts of interest are not connected with the issue of this paper. The other authors have no conflicts of interest to declare.
- Published
- 2019
- Full Text
- View/download PDF
17. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions.
- Author
-
Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, and De Vita F
- Abstract
Gastric cancer (GC) is the fifth-most common cancer worldwide and an important cause of cancer-related-death. The growing knowledge of its molecular pathogenesis has shown that GC is not a single entity, but a constellation of different diseases, each with its own molecular and clinical characteristics. Currently, surgery represents the only curative approach for localized GC, but only 20% of patients (pts) showed resectable disease at diagnosis and, even in case of curative resection, the prognosis remains poor due to the high rate of disease relapse. In this context, multimodal perioperative approaches were developed in western and eastern countries in order to decrease relapse rates and improve survival. However, there is little consensus about the optimal treatment for non-metastatic GC. In this review, we summarize the current status and future developments of perioperative chemotherapy in resectable GC, attempting to find clear answers to the real problems in clinical practice., Competing Interests: Angelica Petrillo: grant from Lilly; Michele Orditura: Honoraria from Italfarmaco, EISAI, epionpharma, Roche; Fortunato Ciardiello: Advisory Boards: Roche, Amgen, Merck, Pfizer, Sanofi, Bayer, Servier, BMS, Celgene, Lilly; Institutional Research Grants: Bayer, Roche, Merck, Amgen, AstraZeneca, Takeda; Ferdinando De Vita: Advisory Boards: Roche, Amgen, Celgene, Lilly. The authors have no conflicts of interest to declare. The funders had no role in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2019
- Full Text
- View/download PDF
18. Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.
- Author
-
Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, and De Vita F
- Subjects
- Adult, Aged, Aged, 80 and over, Blood Platelets, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Lymphocyte Count, Male, Middle Aged, Neutrophils, Prognosis, Retrospective Studies, Stomach Neoplasms drug therapy, Stomach Neoplasms immunology, Biomarkers, Tumor blood, Inflammation blood, Stomach Neoplasms blood
- Abstract
Aim: Systemic inflammatory response affects survival of gastric cancer (GC) patients. This study was carried out to create a prognostic inflammatory-based score to predict survival in metastatic GC (mGC) before first-line chemotherapy., Materials & Methods: We studied the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio in 151 patients with mGC at the diagnosis., Results: Median overall survival (OS) was significantly lower in patients with high NLR. Performance status 1-2 according to the Eastern Cooperative Oncology Group scale and NLR were predictors of shorter OS at multivariate analysis. Based on these results, we defined a prognostic OS score, showing a better median OS in favorable risk group., Conclusion: Elevated pretreatment NLR and Eastern Cooperative Oncology Group are independent predictors of shorter OS in mGC patients before first-line chemotherapy.
- Published
- 2018
- Full Text
- View/download PDF
19. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
- Author
-
Tirino G, Pompella L, Petrillo A, Laterza MM, Pappalardo A, Caterino M, Orditura M, Ciardiello F, Galizia G, and De Vita F
- Subjects
- Animals, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Humans, Immunotherapy methods, Molecular Targeted Therapy methods, Precision Medicine methods, Stomach Neoplasms classification, Stomach Neoplasms genetics, Stomach Neoplasms immunology, Trastuzumab therapeutic use, Ramucirumab, Stomach Neoplasms therapy
- Abstract
Despite some remarkable innovations and the advent of novel molecular classifications the prognosis of patients with advanced gastric cancer (GC) remains overall poor and current clinical application of new advances is disappointing. During the last years only Trastuzumab and Ramucirumab have been approved and currently used as standard of care targeted therapies, but the systemic management of advanced disease did not radically change in contrast with the high number of molecular drivers identified. The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) classifications paved the way, also for GC, to that more contemporary therapeutic approach called "precision medicine" even if tumor heterogeneity and a complex genetic landscape still represent a strong barrier. The identification of specific cancer subgroups is also making possible a better selection of patients that are most likely to respond to immunotherapy. This review aims to critically overview the available molecular classifications summarizing the main druggable molecular drivers and their possible therapeutic implications also taking advantage of new technologies and acquisitions.
- Published
- 2018
- Full Text
- View/download PDF
20. Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.
- Author
-
Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, and De Vita F
- Abstract
Background: High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer., Methods: We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of the CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline NLR, biliary stent implantation, and liver metastasis. Survival analyses were generated according to the Kaplan-Meier method. Univariate and multivariate analyses were performed by a Cox proportional hazard model., Results: According to NLR values, the patients were divided into two groups: high and low. Low group patients showed a better median PFS (7 months versus 5 months) and median OS (13 months versus 7 months) in respect to high group patients. At multivariate analysis, Karnofsky PS < 80% (HR = 0.4; CI 0.2-1.2), liver metastases (HR = 0.4; CI 0.18-0.82), and NLR ≥ 5 (HR = 2.7; 95% CI 1.4-5.2) were predictors of poorer OS. Based on the presence of one or more independent prognostic factors, three risk categories were identified: good-risk, intermediate-risk and poor-risk. The median OS was 22, 10, and 7 months, respectively., Conclusions: Baseline NLR is an independent predictor of survival of patients with mPC receiving palliative chemotherapy and could be useful to develop a simple clinical score to identify a subgroup of patients with a low chance to benefit from chemotherapy.
- Published
- 2018
- Full Text
- View/download PDF
21. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.
- Author
-
Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, and De Vita F
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Humanized, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Ramucirumab, Antibodies, Monoclonal therapeutic use, Stomach Neoplasms drug therapy
- Abstract
Background: Ramucirumab-alone or combined with paclitaxel-represents one of the main options for patients failing first-line treatment for advanced gastric cancer., Objective: The RAMoss study aimed to evaluate the safety and efficacy profile of ramucirumab in the "real-life setting"., Patients and Methods: Patients from 25 Italian hospitals started therapy consisting of ramucirumab 8 mg/kg i.v. d1,15q28 with or without paclitaxel 80 mg/m
2 i.v. d1,8,15q28. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS)., Results: One hundred sixty-seven patients with disease progression on first-line therapy received ramucirumab as monotherapy (10%) or combined with paclitaxel (90%). Median treatment duration was 4 months (1-17 months). Global incidence of grade (G) 3-4 toxicity was 9.6%, and for neutropenia 5.4%; treatment was discontinued due to toxicity in 3% of patients. The most frequent adverse events (AE) were G1-2 fatigue (27.5%), G1-2 neuropathy (26.3%), and G1-2 neutropenia (14.9%). ORR was 20.2%. Stable disease was observed in 39.2% of patients, with a disease control rate of 59.4%. With a median follow-up of 11 months, median PFS was 4.3 months (95% confidence interval [CI] 4.1-4.7), whereas median OS was 8.0 months (95% CI: 7.09-8.9). In a multivariate analysis, ECOG performance status <1 or ≥1 (HR 1.13, 95% CI 1.0-1.27, p = 0.04) and the presence versus absence of peritoneal metastases (HR 1.57, 95% CI 1.63-2.39, p = 0.03) were independent poor prognostic factors., Conclusions: These "real-life" efficacy data on ramucirumab treatment are in line with previous randomized trials. Ramucirumab is well tolerated in daily clinical practice.- Published
- 2018
- Full Text
- View/download PDF
22. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
- Author
-
Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, and Di Bartolomeo M
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological therapeutic use, Case-Control Studies, Female, Humans, Male, Middle Aged, Mutation, Patient Selection, Precision Medicine methods, Progression-Free Survival, Prospective Studies, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 metabolism, Response Evaluation Criteria in Solid Tumors, Stomach Neoplasms genetics, Stomach Neoplasms pathology, Survival Analysis, Trastuzumab pharmacology, Trastuzumab therapeutic use, Antineoplastic Agents, Immunological pharmacology, Biomarkers, Tumor genetics, Drug Resistance, Neoplasm genetics, Stomach Neoplasms drug therapy, Trastuzumab pharmacokinetics
- Abstract
Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical studies have suggested several genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than HER2 or downstream signaling pathways. Experimental Design: We carried out this multicenter, prospective, case-control study to demonstrate the negative predictive impact of a panel of candidate genomic alterations (AMNESIA panel), including EGFR/MET/KRAS/PI3K/PTEN mutations and EGFR/MET/KRAS amplifications. Hypothesizing a prevalence of candidate alterations of 30% and 0% in resistant and sensitive HER2-positive patients, respectively, 20 patients per group were needed. Results: AMNESIA panel alterations were significantly more frequent in resistant (11 of 20, 55%) as compared with sensitive (0% of 17) patients ( P < 0.001), and in HER2 IHC 2
+ (7 of 13, 53.8%) than 3+ (4 of 24, 16.7%) tumors ( P = 0.028). Patients with tumors bearing no candidate alterations had a significantly longer median progression-free [5.2 vs. 2.6 months; HR, 0.34; 95% confidence interval (CI), 0.07-0.48; P = 0.001] and overall survival (16.1 vs. 7.6 months; HR, 0.38; 95% CI, 0.09-0.75; P = 0.015). The predictive accuracy of the AMNESIA panel and HER2 IHC was 76% and 65%, respectively. The predictive accuracy of the combined evaluation of the AMNESIA panel and HER2 IHC was 84%. Conclusions: Our panel of candidate genomic alterations may be clinically useful to predict primary resistance to trastuzumab in patients with HER2-positive metastatic gastric cancer and should be further validated with the aim of molecularly stratifying HER2-addicted cancers for the development of novel treatment strategies. Clin Cancer Res; 24(5); 1082-9. ©2017 AACR ., (©2017 American Association for Cancer Research.)- Published
- 2018
- Full Text
- View/download PDF
23. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
- Author
-
Tehfe M, Tabchi S, Laterza MM, and De Vita F
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm, Esophageal Neoplasms genetics, Esophageal Neoplasms pathology, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Receptor, ErbB-2 genetics, Retreatment, Stomach Neoplasms genetics, Stomach Neoplasms pathology, Trastuzumab therapeutic use, Treatment Outcome, Ramucirumab, Adenocarcinoma drug therapy, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Esophageal Neoplasms drug therapy, Esophagogastric Junction pathology, Stomach Neoplasms drug therapy
- Abstract
Aim: Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials & methods: We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel., Results: Most patients had a stable disease after ramucirumab-based therapy (50%, 5/10), median duration to disease control was 8 months., Conclusion: The prolonged duration of response that we observed indicates that an interaction between the EGF pathway and the angiogenesis pathway requires further clinical investigations.
- Published
- 2018
- Full Text
- View/download PDF
24. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
- Author
-
Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, and De Vita F
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Capecitabine administration & dosage, Cisplatin administration & dosage, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Fluorouracil therapeutic use, Humans, Leucovorin administration & dosage, Leucovorin adverse effects, Leucovorin therapeutic use, Male, Middle Aged, Organoplatinum Compounds administration & dosage, Organoplatinum Compounds adverse effects, Organoplatinum Compounds therapeutic use, Oxaliplatin, Receptor, ErbB-2 metabolism, Retrospective Studies, Stomach Neoplasms pathology, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy, Stomach Neoplasms mortality
- Abstract
The best choice of chemotherapy regimen for patients with metastatic gastric cancer is still debated. Although several studies support a superior efficacy of a triplet chemotherapy regimen over a doublet-based regimen, the magnitude of this benefit appears small and accompanied by an increased toxicity. Based on this background, we evaluated the outcome of patients with HER2-negative metastatic gastric cancer (mGC) who received in the clinical practice a triplet or doublet regimen as first-line therapy. A total of 165 patients (pts) with HER2-negative mGC treated outside of clinical trials at our department with FOLFOX-4 or ECX from 2012 and 2015 were included in our retrospective analysis: FOLFOX-4: 86 pts; ECX: 79 pts. Median progression-free survival (PFS) was 5.1 months for FOLFOX-4 and 5.6 months for ECX regimen, respectively. Median overall survival (OS) was 10.3 months for FOLFOX-4 and 10.9 months for ECX regimens., Toxicity: grade 3-4 vomiting (12.6%), neutropenia (31.6%), mucositis (11.3%) and fatigue (22.7%) occurred more frequently in ECX regimen, while grade 3-4 peripheral neuropathy was more common with FOLFOX-4 (19.7%). Both evaluated regimens are active and safe in the palliation of HER2-negative mGC in the first-line setting: Three-drug chemotherapy regimen appear more active but offer only a slight improvement in OS with an increased G3-G4 toxicity. Our data suggest that a doublet therapy should be preferred in the clinical practice, preferentially reserving a three-drug combination to pts with bulky disease and/or to pts with initially unresectable locally advanced disease.
- Published
- 2017
- Full Text
- View/download PDF
25. Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.
- Author
-
Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F, Savastano C, Cartenì G, Porricelli MA, Berretta M, Pisconti S, Facchini G, and Cavaliere C
- Abstract
In metastatic renal cell carcinoma, complete response to first-line antiangiogenic agents is rare and resistance to therapy often develops. Protocols for sequential treatment with angiogenesis and mTOR inhibitors are under evaluation to improve outcomes. In this observational, real-world study, patients received a first-line therapy with pazopanib until discontinuation for disease progression or toxicity, then a second-line with everolimus. Primary endpoints were overall survival (OS) for sequence, progression free survival (PFS) for each agent, and safety. Thirty-one patients were included in the analysis: 73.3% of patients underwent nephrectomy before treatment, 25.8% had at least three comorbidities. At the beginning of therapy, the median age was 68 years, with more than 60% of patients older than 65 years. The median OS for sequence was 26.5 months (95% CI 17.4-nc); median PFS was 10.6 months (95% CI 6.3-12.1) with pazopanib and 5.3 months (95% CI 3.8-6.7) with everolimus. The median persistence in pazopanib therapy was 8.1 months (Interquartile Range IQR 5.3-12.7), with 31% of patients who required dose reduction, while persistence in everolimus was 4.4 months (IQR 3.4-6.5). Sequence was well tolerated with a different profile of adverse events for each agent. These data confirmed that pazopanib was effective, even in reduced dosing, and well tolerated and suggested that everolimus may represent an opportunity to continue a therapy when patients cannot further tolerate angiogenesis inhibitors or develop a resistance.
- Published
- 2017
- Full Text
- View/download PDF
26. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
- Author
-
Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, and Di Bartolomeo M
- Subjects
- Antineoplastic Agents therapeutic use, Esophageal Neoplasms diagnosis, Esophageal Neoplasms drug therapy, Esophageal Neoplasms genetics, Female, Humans, Immunohistochemistry, Male, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 genetics, Stomach Neoplasms diagnosis, Stomach Neoplasms drug therapy, Stomach Neoplasms genetics, Trastuzumab therapeutic use, Treatment Outcome, Esophageal Neoplasms metabolism, Receptor, ErbB-2 metabolism, Stomach Neoplasms metabolism
- Abstract
Mechanisms of acquired resistance to trastuzumab-based treatment in gastric cancer are largely unknown. In this study, we analyzed 22 pairs of tumor samples taken at baseline and post-progression in patients receiving chemotherapy and trastuzumab for advanced HER2-positive [immunohistochemistry (IHC) 3+ or 2+ with in-situ hybridization (ISH) amplification] gastric or gastroesophageal cancers. Strict clinical criteria for defining acquired trastuzumab resistance were adopted. Loss of HER2 positivity and loss of HER2 over-expression were defined as post-trastuzumab IHC score <3+ and absence of ISH amplification, and IHC "downscoring" from 2+/3+ to 0/1+, respectively. HER2 IHC was always performed, while ISH was missing in 3 post-progression samples. Patients with initial HER2 IHC score 3+ and 2+ were 14 (64%) and 8 (36%), respectively. Loss of HER2 positivity and HER2 over-expression was observed in 32 and 32% samples, respectively. The chance of HER2 loss was not associated with any of the baseline clinicopathological variables. The only exception was in patients with initial IHC score 2+ versus 3+, for both endpoints of HER2 positivity (80 vs. 14%; p = 0.008) and HER2 over-expression (63 vs. 14%; p = 0.025). As already shown in breast cancer, loss of HER2 may be observed also in gastric cancers patients treated with trastuzumab-based chemotherapy in the clinical practice. This phenomenon may be one of the biological reasons explaining the failure of anti-HER2 second-line strategies in initially HER2-positive disease., (© 2016 UICC.)
- Published
- 2016
- Full Text
- View/download PDF
27. Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.
- Author
-
D'Aniello C, Vitale MG, Farnesi A, Calvetti L, Laterza MM, Cavaliere C, Della Pepa C, Conteduca V, Crispo A, De Vita F, Grillone F, Ricevuto E, De Tursi M, De Vivo R, Di Napoli M, Cecere SC, Iovane G, Amore A, Piscitelli R, Quarto G, Pisconti S, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Naglieri E, Galli L, Cartenì G, De Giorgi U, Pignata S, Facchini G, and Rossetti S
- Abstract
Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in second-line treatment of mRCC. The medical records of 62 patients treated with Axitinib, were retrospectively reviewed. The Progression Free Survival (PFS), the Overall Survival (OS), the Objective Response Rate (ORR), the Disease Control Rate (DCR), and the safety profile of axitinib and sunitinib-axitinib sequence, were the primary endpoint. The mPFS was 5.83 months (95% CI 3.93-7.73 months). When patients was stratified by Heng score, mPFS was 5.73, 5.83, 10.03 months according to poor, intermediate, and favorable risk group, respectively. The mOS from the start of axitinib was 13.3 months (95% CI 8.6-17.9 months); the observed ORR and DCR were 25 and 71%, respectively. When stratified patients by subgroups defined by duration of prior therapy with Sunitinib (≤ vs. >median duration), there was a statistically significant difference in mPFS with 8.9 (95% CI 4.39-13.40 months) vs. 5.46 months (95% CI 4.04-6.88 months) for patients with a median duration of Sunitinib >13.2 months. DCR and ORR to previous Sunitinib treatment was associated with longer statistically mPFS, 7.23 (95% CI 3.95-10.51 months, p = 0.01) and 8.67 (95% CI 4.0-13.33 months, p = 0.008) vs. 2.97 (95% CI 0.65-5.27 months, p = 0.01) and 2.97 months (95% CI 0.66-5.28 months, p = 0.01), respectively. Overall Axitinib at standard schedule of 5 mg bid, was well-tolerated. The most common adverse events of all grades were fatig (25.6%), hypertension (22.6%), gastro-intestinal disorders (25.9%), and hypothyroidism (16.1%). The sequence Sunitinib-Axitinib was well-tolerated without worsening in side effects, with a median OS of 34.7 months (95% CI 18.4-51.0 months). Our results are consistent with the available literature; this retrospective analysis confirms that Axitinib is effective and safe in routine clinical practice.
- Published
- 2016
- Full Text
- View/download PDF
28. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
- Author
-
De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, and Orditura M
- Subjects
- Adult, Aged, Albumins therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Compassionate Use Trials, Deoxycytidine administration & dosage, Deoxycytidine therapeutic use, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Paclitaxel therapeutic use, Randomized Controlled Trials as Topic, Retrospective Studies, Survival Analysis, Treatment Outcome, Gemcitabine, Albumins administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Carcinoma, Pancreatic Ductal drug therapy, Deoxycytidine analogs & derivatives, Paclitaxel administration & dosage, Pancreatic Neoplasms drug therapy
- Abstract
Background: Pancreatic adenocarcinoma is an aggressive disease with poor prognosis. In a randomized phase III trial, combination of Nab-paclitaxel (Nab-P) plus gemcitabine showed superior activity and efficacy in first-line treatment compared with gemcitabine alone., Methods: Nab-P is not dispensed in Italy; however, we obtained this drug from our Ethics Committee for compassionate use. The aim of this study was to evaluate the efficacy and safety profile of this Nab-P and gemcitabine combination in a cohort of patients treated outside clinical trials. From January 2012 to May 2014, we included 41 patients with advanced pancreatic adenocarcinoma receiving combination of 125 mg/m(2) Nab-P and 1 g/m(2) gemcitabine on days 1, 8 and 15 of a 28-day cycle, as first-line treatment. Median age of patients was 67 (range 41-77) years, and 11 patients were aged ≥70 years., Results: Eastern Co-operative Oncology Group performance status was 0 or 1 in 32 patients (78 %) and 2 in nine patients (22 %). Primary tumor was located in the pancreatic head or body/tail in 24 (58.5 %) and 17 (41.5 %) patients, respectively, and nine patients had received biliary stent implantation before starting chemotherapy. Median carbohydrate antigen 19-9 level was 469 U/l (range 17.4-61546 U/l) and 29 patients (70.7 %) had referred pain at the time of diagnosis. Patients received a median six cycles (range 1-14) of treatment. Overall response rate was 36.6 %; median progression-free survival was 6.7 months [(95 % confidence interval (CI) 5.966-8.034), and median overall survival was 10 months (95 % CI 7.864-12.136). Treatment was well tolerated. No grade 4 toxicity was reported. Grade 3 toxicity included neutropenia in 10 patients (24.3 %), thrombocytopenia in five (12 %), anemia in three (7.3 %), diarrhea in four (9.7 %), nausea and vomiting in two (4.9 %), and fatigue in six (14.6 %). Finally, pain control was achieved in 24 of 29 patients (82.3 %) with a performance status improvement of 10 % according to the Karnofsky scale., Conclusions: Our results confirm that combination of gemcitabine plus Nab-P is effective both in terms of overall response rate, progression-free survival and overall survival, with a good safety profile.
- Published
- 2016
- Full Text
- View/download PDF
29. Pancreatic neuroendocrine tumors: Nosography, management and treatment.
- Author
-
Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, and De Vita F
- Subjects
- Humans, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Patient Care Team, Neuroendocrine Tumors diagnosis, Neuroendocrine Tumors epidemiology, Neuroendocrine Tumors pathology, Neuroendocrine Tumors surgery, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery
- Abstract
Pancreatic neuroendocrine tumors (pNETs) represent about 7% of all NETs, 8.7% of gastroenteropancreatic NETs (GEP-NETs) and 1-2% of all pancreatic neoplasms. In the last two decades, the increased diagnosis of pNETs has generated great interest and the development of different classifications, grading and staging systems. Recently, several trials were performed in order to improve the knowledge of biomarkers and imaging and to provide an early diagnosis, but their role is still under debate. Nowadays, surgery represents the only curative approach for pNETs. Approximately 90% of pNETs are silent and non-functional; therefore, most patients are diagnosed in late stage and present metastatic (60%) or locally unresectable advanced disease (21%) with a poor prognosis. Not many therapeutic options are available for pNETs, with different treatments for G1-G2 and G3 tumors, because these diseases are still rare and trials are made up of few series of patients. At present, medical treatments is controversial. On these bases, we believe that a multidisciplinary team composed of surgeons, oncologists, endocrinologists, radiation oncologists, radiologists, pathologists and medicals nuclear is required. This paper presents a review of present state-of-the-art in the field of pNETs., (Copyright © 2016. Published by Elsevier Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
30. Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.
- Author
-
Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, and DE Vita F
- Abstract
Bone metastasis is an uncommon event in advanced gastric cancer patients and bone metastases are rarely detected as isolated lesions. However, eleven years after treatment for locally advanced gastric cancer, including total gastrectomy followed by adjuvant chemotherapy, a 49-year-old female was admitted to the IX Division of General Surgery of the Second University of Naples (Naples, Italy) exhibiting severe progressive neurological symptoms. Magnetic resonance imaging indicated vertebral abnormalities, with evidence of marrow infiltration in several vertebral bodies; however, a contrast-enhanced computed tomography scan did not detect disease progression to other sites. Biopsy of the soft tissue at the level of the second lumbar vertebra (L2) revealed a metastatic lesion derived from gastric mucinous adenocarcinoma. The patient was initially treated with radiotherapy directed to the L2-L4 vertebral bodies to control the pain. Subsequently, systemic chemotherapy according to a FOLFOX-4 (leucovorin, fluorouracil and oxaliplatin) regimen commenced. However, after eight cycles, pulmonary progression of the disease occurred. Thus, palliative care was administered and the patient succumbed one month later. The late relapse of gastric cancer in the current patient may be associated with the theory of tumour dormancy.
- Published
- 2015
- Full Text
- View/download PDF
31. Clinical management of advanced gastric cancer: the role of new molecular drugs.
- Author
-
De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, and Orditura M
- Subjects
- Angiogenesis Inhibitors therapeutic use, Animals, Biomarkers, Tumor metabolism, Humans, Protein Kinase Inhibitors therapeutic use, Signal Transduction drug effects, Stomach Neoplasms metabolism, Stomach Neoplasms pathology, Treatment Outcome, Antineoplastic Agents therapeutic use, Biomarkers, Tumor antagonists & inhibitors, Molecular Targeted Therapy, Stomach Neoplasms drug therapy
- Abstract
Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States. Surgery represents the main approach for this disease but, notwithstanding the advances in surgical techniques, we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates. Despite the development of new drugs has significantly improved the effectiveness of chemotherapy, the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor. Recently, several molecular target agents have been investigated; in particular, trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients. New molecules targeting vascular epithelial growth factor, mammalian target of rapamycin, and anti hepatocyte growth factor-c-Met pathway are also under investigation, with interesting results. Anyway, it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results. In this paper we review the actual "scenario" of targeted treatments, also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma, discussing their efficacy and potential applications in clinical practice.
- Published
- 2014
- Full Text
- View/download PDF
32. Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study.
- Author
-
Orditura M, Galizia G, Di Martino N, Ancona E, Castoro C, Pacelli R, Morgillo F, Rossetti S, Gambardella V, Farella A, Laterza MM, Ruol A, Fabozzi A, Napolitano V, Iovino F, Lieto E, Fei L, Conzo G, Ciardiello F, and De Vita F
- Abstract
Background: To date, few studies of preoperative chemotherapy or chemoradiotherapy (crt) in gastroesophageal junction (gej) cancer have been statistically powered; indeed, gej tumours have thus far been grouped with esophageal or gastric cancer in phase iii trials, thereby generating conflicting results., Methods: We studied 41 patients affected by locally advanced Siewert type i and ii gej adenocarcinoma who were treated with a neoadjuvant crt regimen [folfox4 (leucovorin-5-fluorouracil-oxaliplatin) for 4 cycles, and concurrent computed tomography-based three-dimensional conformal radiotherapy delivered using 5 daily fractions of 1.8 Gy per week for a total dose of 45 Gy], followed by surgery. Completeness of tumour resection (performed approximately 6 weeks after completion of crt), clinical and pathologic response rates, and safety and outcome of the treatment were the main endpoints of the study., Results: All 41 patients completed preoperative treatment. Combined therapy was well tolerated, with no treatment-related deaths. Dose reduction was necessary in 8 patients (19.5%). After crt, 78% of the patients showed a partial clinical response, 17% were stable, and 5% experienced disease progression. Pathology examination of surgical specimens demonstrated a 10% complete response rate. The median and mean survival times were 26 and 36 months respectively (95% confidence interval: 14 to 37 months and 30 to 41 months respectively). On multivariate analysis, TNM staging and clinical response were demonstrated to be the only independent variables related to long-term survival., Conclusions: In our experience, preoperative chemoradiotherapy with folfox4 is feasible in locally advanced gej adenocarcinoma, but shows mild efficacy, as suggested by the low rate of pathologic complete response.
- Published
- 2014
- Full Text
- View/download PDF
33. Treatment of gastric cancer.
- Author
-
Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, and De Vita F
- Subjects
- Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemoradiotherapy methods, Chemotherapy, Adjuvant methods, Cisplatin administration & dosage, Clinical Trials as Topic, Fluorouracil administration & dosage, Humans, Neoplasm Metastasis, Palliative Care methods, Radiotherapy methods, Receptor, ErbB-2 metabolism, Trastuzumab, Stomach Neoplasms drug therapy, Stomach Neoplasms radiotherapy, Stomach Neoplasms surgery
- Abstract
The authors focused on the current surgical treatment of resectable gastric cancer, and significance of peri- and post-operative chemo or chemoradiation. Gastric cancer is the 4(th) most commonly diagnosed cancer and the second leading cause of cancer death worldwide. Surgery remains the only curative therapy, while perioperative and adjuvant chemotherapy, as well as chemoradiation, can improve outcome of resectable gastric cancer with extended lymph node dissection. More than half of radically resected gastric cancer patients relapse locally or with distant metastases, or receive the diagnosis of gastric cancer when tumor is disseminated; therefore, median survival rarely exceeds 12 mo, and 5-years survival is less than 10%. Cisplatin and fluoropyrimidine-based chemotherapy, with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients, is the widely used treatment in stage IV patients fit for chemotherapy. Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance status.
- Published
- 2014
- Full Text
- View/download PDF
34. Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer.
- Author
-
Morgillo F, De Vita F, Antoniol G, Orditura M, Auriemma PP, Diadema MR, Lieto E, Savastano B, Festino L, Laterza MM, Fabozzi A, Ventriglia J, Petrillo A, Ciardiello F, Barbarisi A, and Iovino F
- Abstract
Increased insulin-like growth factor (igf) signalling has been observed in breast cancer, including endocrine-responsive cancers, and has been linked to disease progression and recurrence. In particular, igf-1 has the ability to induce and promote lymphangiogenesis through the induction of vascular endothelial growth factor C (vegfc). In the present study, we analyzed serum and tumour samples from 60 patients with endocrine-positive breast cancer to determine the expression and the possible relationship of circulating igf-1, igf binding protein 3 (igfbp3), and vegfc with the presence of lymphatic metastasis and other immunohistochemical parameters. The analysis revealed a clear and significant correlation between high basal levels of igf-1, igfbp3, and vegfc and lymph node metastasis in endocrine-responsive breast cancer. In addition, expression of those molecules was significantly higher in breast cancer patients than in healthy control subjects. Those findings may enable more accurate prediction of prognosis in patients with breast cancer.
- Published
- 2013
- Full Text
- View/download PDF
35. Gefitinib in non-small cell lung carcinoma: a case report of an unusual side effect and complete response in advanced disease.
- Author
-
Laterza MM, Chiurazzi B, Brangi M, Riccardi F, and Cartenì G
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung metabolism, ErbB Receptors metabolism, Fluorodeoxyglucose F18, Gefitinib, Humans, Lung Neoplasms diagnosis, Lung Neoplasms metabolism, Male, Middle Aged, Positron-Emission Tomography methods, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Quinazolines administration & dosage, Quinazolines adverse effects, Remission Induction, Tomography, X-Ray Computed, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Cystitis chemically induced, ErbB Receptors drug effects, Hemorrhage chemically induced, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Protein-Tyrosine Kinases antagonists & inhibitors, Quinazolines therapeutic use
- Abstract
Gefitinib is a tyrosine kinase inhibitor, indicated in advanced non-small cell lung cancer in all lines of treatment for patients harboring EGFR mutations. It has a favorable toxicity profile but may induce unexpected adverse effects, such as an infiammatory reaction in the bladder. We report a rare case of hemorrhagic cystitis, an unusual side effect, in a patient with non-small cell lung cancer treated with gefitinib, which did not compromise the clinical response.
- Published
- 2013
- Full Text
- View/download PDF
36. Malignant melanoma metastasizing to the uterus in a patient with atypical postmenopause metrorrhagia. A case report.
- Author
-
Simeone S, Laterza MM, Scaravilli G, Capuano S, Serao M, Orabona P, Rossi R, and Balbi C
- Subjects
- Biopsy, Diagnosis, Differential, Endometrial Neoplasms diagnosis, Endometrial Neoplasms surgery, Female, Humans, Hysterectomy methods, Hysteroscopy methods, Immunohistochemistry, Melanoma diagnosis, Melanoma surgery, Middle Aged, Skin Neoplasms diagnosis, Skin Neoplasms surgery, Treatment Outcome, Endometrial Neoplasms complications, Endometrial Neoplasms secondary, Melanoma complications, Melanoma secondary, Metrorrhagia etiology, Postmenopause, Skin Neoplasms pathology
- Abstract
Unlabelled: The uterine metastases of melanoma are very rare. At the present time, only one case occurred in our department., Case Report: a 54-year-old plurigravid woman showed a metrorrhagia of unknown origin. The patient underwent a diagnostic hysteroscopy and an endometrial biopsy, in order to investigate the symptomatic postmenopausal bleeding and exclude a neoplasia, such as the endometrial carcinoma. The patient was discharged with a diagnosis of uterine fibromatosis and called back to go through a complete laparoscopic hysterectomy and bilateral adnexectomy. During the operation, some metastases were found in the genital tract. An accurate physical examination allowed us to discover a cutaneous nevus, the excision and histology of which revealed its malignancy. The immunohistochemistry of the surgical sample was able to confirm the hypothesized relationship between the nevus and the metastases, thus leading to the diagnosis of malignant melanoma metastases, genital tract. It is important to make an accurate diagnostic passage to exclude tumoral pathology in patients with atypical uterine bleeding. Every uterine bleeding of the postmenopausal period (abnormal uterine bleeding, AUB) is considered atypical and it has to be early investigated, in order to exclude any endometrial cancer. The nature of the uterine bleedings can be ascribed to atrophy, dysfunctional matters (dysfunctional uterine bleeding, DBU), benign organic alterations, only in 7-10% of cases to endometrial cancer and more rarely to metastatic tumours, as well as this case of melanoma. Physicians should be aware of such unusual possibilities in order to look carefully for metastatic implants in adenomyomas.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.